Literature DB >> 24168793

Pulmonary hypertension related to congenital heart disease: a call for action.

Konstantinos Dimopoulos1, Stephen John Wort, Michael A Gatzoulis.   

Abstract

Pulmonary arterial hypertension related to congenital heart disease (PAH-CHD) is a common type of pulmonary arterial hypertension (PAH). Despite this, little emphasis has been given to this group of patients until recently, when compared with idiopathic PAH. This is largely because of the complexity and the wide range of underlying cardiac anatomy and physiology, with a multitude of adaptive mechanisms not fully understood. Pulmonary arterial hypertension related to congenital heart disease is, therefore, best diagnosed and managed in centres specializing in both CHD and PAH, to avoid common pitfalls and old practices and to provide state-of-the-art care. We discuss the optimal management of PAH-CHD patients in a series of actions to be taken in order to optimize short- and long-term outcome, based on current knowledge of the condition and the advent of targeted advanced therapies.

Entities:  

Keywords:  Advanced therapies; Congenital heart disease; Eisenmenger syndrome; Pulmonary hypertension; Pulmonary vascular disease; Targeted therapies; Treat and repair

Mesh:

Year:  2013        PMID: 24168793     DOI: 10.1093/eurheartj/eht437

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  28 in total

1.  Pulmonary Hypertension in Children - a Practical Approach.

Authors:  Eliza Cinteza; Alin Nicolescu; Cristina Filip; Andrei Lupu; Georgiana Nicolae; Gabriela Duica; Mihaela Balgradean
Journal:  Maedica (Buchar)       Date:  2015-09

2.  What is your diagnosis?

Authors:  Yavuzer Koza; Ferhat Kanbay; Muhammed Hakan Tas; Fatih Alper
Journal:  Anatol J Cardiol       Date:  2021-01       Impact factor: 1.596

3.  Acute Effect of Inhaled Iloprost in Children with Pulmonary Arterial Hypertension Associated with Simple Congenital Heart Defects.

Authors:  Qiangqiang Li; Konstantinos Dimopoulos; Chen Zhang; Yan Zhu; Qian Liu; Hong Gu
Journal:  Pediatr Cardiol       Date:  2018-02-09       Impact factor: 1.655

4.  Frontiers in congenital heart disease: pulmonary hypertension, heart failure, and arrhythmias.

Authors:  Thomas F Lüscher
Journal:  Eur Heart J       Date:  2016-05-07       Impact factor: 29.983

5.  A novel NKX2.6 mutation associated with congenital ventricular septal defect.

Authors:  Juan Wang; Jian-Hui Mao; Ke-Ke Ding; Wei-Jun Xu; Xing-Yuan Liu; Xing-Biao Qiu; Ruo-Gu Li; Xin-Kai Qu; Ying-Jia Xu; Ri-Tai Huang; Song Xue; Yi-Qing Yang
Journal:  Pediatr Cardiol       Date:  2014-11-08       Impact factor: 1.655

6.  A Novel TBX1 Loss-of-Function Mutation Associated with Congenital Heart Disease.

Authors:  Yun Pan; Zha-Gen Wang; Xing-Yuan Liu; Hong Zhao; Ning Zhou; Gui-Fen Zheng; Xing-Biao Qiu; Ruo-Gu Li; Fang Yuan; Hong-Yu Shi; Xu-Min Hou; Yi-Qing Yang
Journal:  Pediatr Cardiol       Date:  2015-04-10       Impact factor: 1.655

7.  Advanced therapies in patients with congenital heart disease-related pulmonary arterial hypertension: results from a long-term, single center, real-world follow-up.

Authors:  Silvia Favilli; Gaia Spaziani; Piercarlo Ballo; Veronica Fibbi; Gennaro Santoro; Enrico Chiappa; Chiara Arcangeli
Journal:  Intern Emerg Med       Date:  2015-01-09       Impact factor: 3.397

Review 8.  Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics.

Authors:  D B Frank; B D Hanna
Journal:  Minerva Pediatr       Date:  2015-01-21       Impact factor: 1.312

9.  Current therapy and outcome of Eisenmenger syndrome: data of the German National Register for congenital heart defects.

Authors:  Gerhard-Paul Diller; Marc-André Körten; Ulrike M M Bauer; Oliver Miera; Oktay Tutarel; Harald Kaemmerer; Felix Berger; Helmut Baumgartner
Journal:  Eur Heart J       Date:  2016-02-02       Impact factor: 29.983

Review 10.  Adult congenital heart disease with pulmonary arterial hypertension: mechanisms and management.

Authors:  Michail Papamichalis; Andrew Xanthopoulos; Panagiotis Papamichalis; John Skoularigis; Filippos Triposkiadis
Journal:  Heart Fail Rev       Date:  2020-09       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.